83 related articles for article (PubMed ID: 7660854)
21. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
22. Ethanol decreases the efficiency of phosphorylation of thymidine kinase in a human T-lymphocytic cell line.
Prakash O; Tang ZY; Zhou P; Peng X; Kolls J; Shellito JE; Nelson S
Alcohol Clin Exp Res; 2002 Mar; 26(3):295-302. PubMed ID: 11923581
[TBL] [Abstract][Full Text] [Related]
23. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
24. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
25. An in-house assay for serum deoxythymidine kinase.
Seah LH; Ton SH; Cheong SK; Hamidah NH
Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
[TBL] [Abstract][Full Text] [Related]
26. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
27. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
28. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
29. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
Lehtinen T
Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
[TBL] [Abstract][Full Text] [Related]
30. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
31. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
Rasey JS; Grierson JR; Wiens LW; Kolb PD; Schwartz JL
J Nucl Med; 2002 Sep; 43(9):1210-7. PubMed ID: 12215561
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
[TBL] [Abstract][Full Text] [Related]
33. Applicability of international prognostic index in non Hodgkin's lymphoma in Pakistan.
Aziz Z; Sana S; Saeed S; Akram M
J Ayub Med Coll Abbottabad; 2004; 16(2):15-20. PubMed ID: 15455610
[TBL] [Abstract][Full Text] [Related]
34. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
35. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
36. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
37. Significance of thymidine kinase activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Nakao M; Miki T
J Urol; 2003 Feb; 169(2):706-9. PubMed ID: 12544347
[TBL] [Abstract][Full Text] [Related]
38. [Basic examination of deoxythymidine kinase using Prolifigen TK kit "Daiichi"].
Sadamori N; Yamaguchi K; Hakariya S; Mine M; Hayashibara T; Kawachi T; Sasagawa I; Iwasaki H; Kinoshita H; Hayashi K
Rinsho Ketsueki; 1990 Nov; 31(11):1806-11. PubMed ID: 2287065
[TBL] [Abstract][Full Text] [Related]
39. Thymidine kinase assay in canine lymphoma.
Elliott JW; Cripps P; Blackwood L
Vet Comp Oncol; 2013 Mar; 11(1):1-13. PubMed ID: 22236202
[TBL] [Abstract][Full Text] [Related]
40. [The enzymatic character of myeloma cell].
Yoshikawa O; Furuya T; Toyama K
Nihon Rinsho; 1995 Mar; 53(3):598-602. PubMed ID: 7699891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
